Follow us on:

Linkedin Facebook

Health

Companies engaged in biotechnology, pharmaceuticals, research services, home healthcare, hospital operations, long‑term care, and the manufacture and supply of medical equipment and supplies. The sector also includes pharmaceutical retailers and providers of health‑information services. UK‑listed companies in this sector include AstraZeneca plc, GlaxoSmithKline plc, Smith & Nephew plc, Hikma Pharmaceuticals plc, ConvaTec Group plc, Spire Healthcare plc and EMIS Group plc.

Physicians Capital

Understanding what really drives medical property value

In medical property investment, valuation is about understanding how risk, lease structure, and investor conviction converge to define true worth...
Aptamer Group

Aptamer Group delivers 40% revenue growth and expands licensing portfolio

Aptamer Group has announced its full-year results for the twelve months ended 30 June 2025, delivering a 40% increase in revenue to £1.2 million and expanding its Optimer® licensing portfolio from four to eleven assets...
Aptamer

Aptamer Group secures repeat contract for Optimer® binder development

Aptamer Group has signed a new agreement with an existing partner to develop Optimer® binders targeting two proteins for biomarker research...
AstraZeneca

AstraZeneca Plc reaches agreement with Trump administration to cut US drug prices

AstraZeneca has signed a landmark agreement with President Donald J. Trump’s administration to reduce the cost of prescription medicines for American patients...
Nuformix plc

Nuformix appoints Kreston Reeves Audit as new auditor

Nuformix has appointed Kreston Reeves Audit LLP as its new auditor following the restructuring of Kreston Reeves LLP...
Aptamer

Aptamer Group to announce full year 2025 results on 14 October

Aptamer Group will publish results for the year ended 30 June 2025 on Tuesday, 14 October 2025, with an online analyst briefing at 9.30 am hosted by CEO Dr Arron Tolley and CFO Andrew Rapson. ...
Smith & Nephew plc

Smith & Nephew to host Capital Markets Days in London and New York

Smith & Nephew will hold Capital Markets Days on 8 December in London and 11 December in New York to outline its new strategy, mid-term priorities, and portfolio growth plans...
Aptamer Group

Aptamer Group secures £360,000 contract with top 3 global pharma

Aptamer Group has signed a £360,000 development contract with a leading global pharmaceutical company to engineer Optimer® binders as targeted radiopharmaceuticals...
EDX Medical

EDX Medical launches TC100, UK’s most advanced testicular cancer testing service

EDX Medical Group plc has commenced marketing its TC100 testicular cancer testing service, described as the most advanced of its kind in the UK...
Physicians Capital

When physicians turn practice into property

Physicians are increasingly turning to medical real estate to convert income into lasting ownership, transforming their practices into legacy assets that outlive their careers...
Cizzle Bio

Cizzle Biotechnology strengthens North American rollout of CIZ1B lung cancer test (LON:CIZ)

Cizzle Biotechnology Executive Chairman Dr Allan Syms spoke with DirectorsTalk about the company’s interim results and progress in commercialising its CIZ1B blood test for the early detection of lung cancer...
One Health Group plc

One Health Group outlines strong H1 growth and NHS-focused expansion plans

Chairman Derek Bickerstaff discusses One Health Group’s first half performance, driven by higher referrals, more surgeons and increased operating capacity...

Cizzle Biotechnology US Rollout Begins as Lung Cancer Test Moves from Lab to Clinic (Video)

Cizzle Biotechnology is now in commercial motion, with its lung cancer diagnostic test entering clinical validation across North America. Backed by Cizzle Bio, OmniHealth, and the Moffitt Cancer Center, the company is moving from lab bench to nationwide rollout — with royalty payments already in hand...
GSK Plc

GSK Plc names Luke Miels as CEO Designate, effective January 2026

GSK has announced the appointment of Luke Miels as CEO Designate, with full responsibilities and a Board position from 1 January 2026. Currently Chief Commercial Officer, Luke has been key in expanding GSK’s specialty medicines and vaccines portfolio, bringing senior experience from AstraZeneca, Roche and Sanofi-Aventis...
Cizzle Biotechnology Holdings

Cizzle Biotechnology expands North American rollout of CIZ1B lung cancer test

Cizzle Biotechnology has confirmed further progress in the US launch of its CIZ1B biomarker test through exclusive partner Cizzle Bio Inc, which is completing validation with Omni Health Diagnostics...
Aptamer Group

Aptamer Group to present at ShareSoc Growth Company seminar in Leeds

Aptamer will present at the ShareSoc Growth Company Seminar on Wednesday, 8 October 2025, at the Leonardo Hotel, Leeds. CEO Dr Arron Tolley and CFO Andrew Rapson will update investors on the Company’s progress, with a recording of the presentation to be published on the Aptamer website after the event...
Halma plc

Halma Plc lifts FY revenue growth guidance in trading update

Halma plc reported strong progress in the first half of its financial year to 30 September 2025, raising full-year revenue growth guidance to low double-digit organic constant currency growth, up from upper single digits...
Nuformix plc

Nuformix to present NXP002 data at ERS Congress 2025

Nuformix will attend the European Respiratory Society Congress in Amsterdam from 28 September 2025, where it will present new findings from its lead programme, NXP002, an inhaled treatment for idiopathic pulmonary fibrosis...
AstraZeneca

AstraZeneca’s Tezspire recommended for EU approval in chronic rhinosinusitis with nasal polyps

The European Medicines Agency’s CHMP has issued a positive opinion recommending approval of Tezspire (tezepelumab) for adult patients with chronic rhinosinusitis with nasal polyps...
Roquefort Therapeutics

Roquefort Therapeutics Stephen West analyses value of US acquisition (LON:ROQ)

Roquefort Therapeutics Executive Chairman Stephen West discusses the company’s proposed £30 million reverse takeover of Coiled Therapeutics. The deal, supported by a £6 million investment from A2A Pharmaceuticals and its investors, will pivot Roquefort into a clinical-stage biotech, adding AO-252, a novel TACC3-targeting cancer therapy already in Phase I trials, to its pipeline...

News and Interview Alerts

Subscribe Free

Company Presentations

Q&As

Hardman & Co

Green News

View all Sustainable sectors, Plcs and news >>  

Search

Search

Latest Interviews

BrokerTalk

Funds

View all Funds, Market Insights and news >> 

FTSE 100 News

UK Broker Ratings

November 24, 2025

Physicians Capital

Understanding what really drives medical property value

In medical property investment, valuation is about understanding how risk, lease structure, and investor conviction converge to define true worth...
Aptamer Group

Aptamer Group delivers 40% revenue growth and expands licensing portfolio

Aptamer Group has announced its full-year results for the twelve months ended 30 June 2025, delivering a 40% increase in revenue to £1.2 million and expanding its Optimer® licensing portfolio from four to eleven assets...
Aptamer

Aptamer Group secures repeat contract for Optimer® binder development

Aptamer Group has signed a new agreement with an existing partner to develop Optimer® binders targeting two proteins for biomarker research...
AstraZeneca

AstraZeneca Plc reaches agreement with Trump administration to cut US drug prices

AstraZeneca has signed a landmark agreement with President Donald J. Trump’s administration to reduce the cost of prescription medicines for American patients...
Nuformix plc

Nuformix appoints Kreston Reeves Audit as new auditor

Nuformix has appointed Kreston Reeves Audit LLP as its new auditor following the restructuring of Kreston Reeves LLP...
Aptamer

Aptamer Group to announce full year 2025 results on 14 October

Aptamer Group will publish results for the year ended 30 June 2025 on Tuesday, 14 October 2025, with an online analyst briefing at 9.30 am hosted by CEO Dr Arron Tolley and CFO Andrew Rapson. ...
Smith & Nephew plc

Smith & Nephew to host Capital Markets Days in London and New York

Smith & Nephew will hold Capital Markets Days on 8 December in London and 11 December in New York to outline its new strategy, mid-term priorities, and portfolio growth plans...
Aptamer Group

Aptamer Group secures £360,000 contract with top 3 global pharma

Aptamer Group has signed a £360,000 development contract with a leading global pharmaceutical company to engineer Optimer® binders as targeted radiopharmaceuticals...
EDX Medical

EDX Medical launches TC100, UK’s most advanced testicular cancer testing service

EDX Medical Group plc has commenced marketing its TC100 testicular cancer testing service, described as the most advanced of its kind in the UK...
Physicians Capital

When physicians turn practice into property

Physicians are increasingly turning to medical real estate to convert income into lasting ownership, transforming their practices into legacy assets that outlive their careers...
Cizzle Bio

Cizzle Biotechnology strengthens North American rollout of CIZ1B lung cancer test (LON:CIZ)

Cizzle Biotechnology Executive Chairman Dr Allan Syms spoke with DirectorsTalk about the company’s interim results and progress in commercialising its CIZ1B blood test for the early detection of lung cancer...
One Health Group plc

One Health Group outlines strong H1 growth and NHS-focused expansion plans

Chairman Derek Bickerstaff discusses One Health Group’s first half performance, driven by higher referrals, more surgeons and increased operating capacity...

Cizzle Biotechnology US Rollout Begins as Lung Cancer Test Moves from Lab to Clinic (Video)

Cizzle Biotechnology is now in commercial motion, with its lung cancer diagnostic test entering clinical validation across North America. Backed by Cizzle Bio, OmniHealth, and the Moffitt Cancer Center, the company is moving from lab bench to nationwide rollout — with royalty payments already in hand...
GSK Plc

GSK Plc names Luke Miels as CEO Designate, effective January 2026

GSK has announced the appointment of Luke Miels as CEO Designate, with full responsibilities and a Board position from 1 January 2026. Currently Chief Commercial Officer, Luke has been key in expanding GSK’s specialty medicines and vaccines portfolio, bringing senior experience from AstraZeneca, Roche and Sanofi-Aventis...
Cizzle Biotechnology Holdings

Cizzle Biotechnology expands North American rollout of CIZ1B lung cancer test

Cizzle Biotechnology has confirmed further progress in the US launch of its CIZ1B biomarker test through exclusive partner Cizzle Bio Inc, which is completing validation with Omni Health Diagnostics...
Aptamer Group

Aptamer Group to present at ShareSoc Growth Company seminar in Leeds

Aptamer will present at the ShareSoc Growth Company Seminar on Wednesday, 8 October 2025, at the Leonardo Hotel, Leeds. CEO Dr Arron Tolley and CFO Andrew Rapson will update investors on the Company’s progress, with a recording of the presentation to be published on the Aptamer website after the event...
Halma plc

Halma Plc lifts FY revenue growth guidance in trading update

Halma plc reported strong progress in the first half of its financial year to 30 September 2025, raising full-year revenue growth guidance to low double-digit organic constant currency growth, up from upper single digits...
Nuformix plc

Nuformix to present NXP002 data at ERS Congress 2025

Nuformix will attend the European Respiratory Society Congress in Amsterdam from 28 September 2025, where it will present new findings from its lead programme, NXP002, an inhaled treatment for idiopathic pulmonary fibrosis...
AstraZeneca

AstraZeneca’s Tezspire recommended for EU approval in chronic rhinosinusitis with nasal polyps

The European Medicines Agency’s CHMP has issued a positive opinion recommending approval of Tezspire (tezepelumab) for adult patients with chronic rhinosinusitis with nasal polyps...
Roquefort Therapeutics

Roquefort Therapeutics Stephen West analyses value of US acquisition (LON:ROQ)

Roquefort Therapeutics Executive Chairman Stephen West discusses the company’s proposed £30 million reverse takeover of Coiled Therapeutics. The deal, supported by a £6 million investment from A2A Pharmaceuticals and its investors, will pivot Roquefort into a clinical-stage biotech, adding AO-252, a novel TACC3-targeting cancer therapy already in Phase I trials, to its pipeline...
Load More

News and Interview Alerts

Subscribe Free

Company Presentations

Q&As

Hardman & Co

Green News

View all Sustainable sectors, Plcs and news >>  

Search

Search

Latest interviews

Broker Talk

Funds

View all Funds, Market Insights and news >> 

FTSE 100 News

UK Broker Ratings

Health

Latest Interviews

FTSE 100 News

FTSE 250 News

News and Interview Alerts

Subscribe Free

Company Presentations

Q&As

Hardman & Co

BrokerTalk

FTSE 100

Funds

View all Funds, Market Insights and news >> 

Green News

View all Sustainable sectors, Plcs and news >>  

UK Broker Ratings

Follow us on Social Media:

Home X-twitter Linkedin Facebook Spotify Apple